About this trial
This is a prospective, non-randomized, non-blinded observational study. The overarching goal is to discover new disease-associated genes in children, while establishing a specific focus on disorders where molecular characterization is most likely to lead to novel therapies. This study will merge detailed phenotypic characterization of patients presenting to the Pediatric Genetics and Metabolism Division in the Department of Pediatrics/Children's Medical Center at Dallas and collaborating clinics with Next-Generation sequencing techniques to identify disease-producing mutations. The primary objective of the study is to identify novel pathogenic mutations in children with rare Mendelian disorders. A secondary objective of the study is to establish normative ranges of a large number of metabolites from healthy newborns and older children.
Eligibility criteria
Qualifiers
Subjects aged 1-2 days
Subjects with gestational age 37-42 weeks
Subjects with stable clinical status (admitted to normal newborn nursery)
Confirmed metabolic or genetic diseases
Disqualifiers
Subjects with gestational age <37 weeks or >42 weeks
Subjects with overt signs of metabolic dysfunction, distress or genetic diseases including hypoglycemia, hyperglycemia, sepsis/shock, hypoxemia, or major congenital malformation
Subjects with mothers whose pregnancies were complicated by gestational diabetes, gestational hyperglycemia, gestational hypertension, preeclampsia, or any other major disorders.
Subjects with confirmed metabolic or genetic diseases
Trial design
Treatments tested in this trial
- Skin Biopsy